Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.

Join us as we dived into:

• The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
• Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from the MajesTEC-3 and MajesTEC-9 studies.
• The promising data around talquetamab from the MonumenTAL-3 study, highlighting its significant progression-free survival (PFS) improvement.
• An overview of mezigdomide, a new immunomodulatory agent, and its impact on treatment strategies for anti-CD38 and lenalidomide-refractory patients.

We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.

Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!

Listen to us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.

Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.

Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.

Topics Covered:

• Current treatment options for relapsed multiple myeloma

• Insights from the MajesTEC-3 and MajesTEC-9 studies

• The role of bispecific antibodies and CAR-T therapies

• Managing side effects and patient care strategies

• The importance of community and academic partnerships

Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Tune in now and stay informed about the latest in oncology!

#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs,#OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.

We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.

Key topics covered in this episode included:

• The role of next-generation sequencing (NGS) in guiding treatment options
• Choosing between dual checkpoint inhibitors and IO-TKI combinations
• Managing side effects associated with various treatment regimens
• Sequencing treatment options for patients who progress after initial therapy
• Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!

#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI,#OncologyBrothers